Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 4/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745795 | 0.85 | CRBN (0.47) | CRBNNR1H2NR1H3RBP4TTR | |
| SCHEMBL12525385 | 0.81 | CRBN (0.50) | CRBNNR1H2NR1H3RBP4TTR | |
| SCHEMBL20534016 | 0.79 | CRBN (0.48) | CRBNNR1H2NR1H3RBP4HCRTR1 | |
| SCHEMBL20745082 | 0.78 | CRBN (0.47) | CRBNNR1H2NR1H3RBP4HCRTR1 | |
| SCHEMBL17515578 | 0.76 | HCRTR2 (0.47) | CRBNNR1H2NR1H3RBP4HCRTR1 | |
| SCHEMBL22320481 | 0.76 | NR1H2 (0.39) | NR1H2HCRTR1HCRTR2 | |
| SCHEMBL28059117 | 0.75 | CRBN (0.55) | CRBNNR1H2NR1H3RBP4ACACB | |
| SCHEMBL31704799 | 0.74 | CRBN (0.52) | CRBNNR1H2NR1H3RBP4TTR | |
| SCHEMBL17465981 | 0.73 | RBP4 (0.54) | CRBNNR1H2NR1H3RBP4HCRTR1 | |
| SCHEMBL20745726 | 0.73 | CRBN (0.53) | CRBNCYP2C19ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | CRBN 482/4885NR1H2 3570/4885NR1H3 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.